| Ari Michael Steiner, MD | |
|
224 Seventh St, Garden City, NY 11530 | |
| (516) 474-0161 | |
| (516) 747-0166 |
| Full Name | Ari Michael Steiner |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 22 Years |
| Location | 224 Seventh St, Garden City, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215101175 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 234670 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mount Sinai South Nassau | Oceanside, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Icahn School Of Medicine At Mount Sinai | 8527473479 | 17 |
News Archive
A new analysis of existing research offers confirmation that taking a break from AIDS drugs is a bad idea for HIV patients with uncontrolled cases of the disease.
Delaying treatment for rheumatoid arthritis could greatly increase the likelihood that patients will suffer joint damage and experience disability two years out, according to a new study from Vivian Bykerk, M.D. at Hospital for Special Surgery. The research will be presented at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals on October 28 in San Diego.
A new study published in the latest edition of a leading medical journal has shown that treatment with ULTRACET® (37.5 mg tramadol hydrochloride/325 mg acetaminophen tablets) demonstrates similar efficacy and better tolerability than TYLENOL® with Codeine No. 3 when each is compared to placebo.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted an investigational new drug application (IND) to the Food and Drug Administration for a first-in-human study of RX-5902 to treat advanced or metastatic solid tumors.
› Verified 7 days ago
| Entity Name | Steven S Shayani Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972531564 PECOS PAC ID: 5991697880 Enrollment ID: O20040325001716 |
News Archive
A new analysis of existing research offers confirmation that taking a break from AIDS drugs is a bad idea for HIV patients with uncontrolled cases of the disease.
Delaying treatment for rheumatoid arthritis could greatly increase the likelihood that patients will suffer joint damage and experience disability two years out, according to a new study from Vivian Bykerk, M.D. at Hospital for Special Surgery. The research will be presented at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals on October 28 in San Diego.
A new study published in the latest edition of a leading medical journal has shown that treatment with ULTRACET® (37.5 mg tramadol hydrochloride/325 mg acetaminophen tablets) demonstrates similar efficacy and better tolerability than TYLENOL® with Codeine No. 3 when each is compared to placebo.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted an investigational new drug application (IND) to the Food and Drug Administration for a first-in-human study of RX-5902 to treat advanced or metastatic solid tumors.
› Verified 7 days ago
| Entity Name | Sn Radiological Practice Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275837882 PECOS PAC ID: 6507049947 Enrollment ID: O20110323000348 |
News Archive
A new analysis of existing research offers confirmation that taking a break from AIDS drugs is a bad idea for HIV patients with uncontrolled cases of the disease.
Delaying treatment for rheumatoid arthritis could greatly increase the likelihood that patients will suffer joint damage and experience disability two years out, according to a new study from Vivian Bykerk, M.D. at Hospital for Special Surgery. The research will be presented at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals on October 28 in San Diego.
A new study published in the latest edition of a leading medical journal has shown that treatment with ULTRACET® (37.5 mg tramadol hydrochloride/325 mg acetaminophen tablets) demonstrates similar efficacy and better tolerability than TYLENOL® with Codeine No. 3 when each is compared to placebo.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted an investigational new drug application (IND) to the Food and Drug Administration for a first-in-human study of RX-5902 to treat advanced or metastatic solid tumors.
› Verified 7 days ago
| Entity Name | Icahn School Of Medicine At Mount Sinai |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477177400 PECOS PAC ID: 8527473479 Enrollment ID: O20210226001533 |
News Archive
A new analysis of existing research offers confirmation that taking a break from AIDS drugs is a bad idea for HIV patients with uncontrolled cases of the disease.
Delaying treatment for rheumatoid arthritis could greatly increase the likelihood that patients will suffer joint damage and experience disability two years out, according to a new study from Vivian Bykerk, M.D. at Hospital for Special Surgery. The research will be presented at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals on October 28 in San Diego.
A new study published in the latest edition of a leading medical journal has shown that treatment with ULTRACET® (37.5 mg tramadol hydrochloride/325 mg acetaminophen tablets) demonstrates similar efficacy and better tolerability than TYLENOL® with Codeine No. 3 when each is compared to placebo.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted an investigational new drug application (IND) to the Food and Drug Administration for a first-in-human study of RX-5902 to treat advanced or metastatic solid tumors.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ari Michael Steiner, MD 224 Seventh St, Garden City, NY 11530 Ph: (516) 474-0161 | Ari Michael Steiner, MD 224 Seventh St, Garden City, NY 11530 Ph: (516) 474-0161 |
News Archive
A new analysis of existing research offers confirmation that taking a break from AIDS drugs is a bad idea for HIV patients with uncontrolled cases of the disease.
Delaying treatment for rheumatoid arthritis could greatly increase the likelihood that patients will suffer joint damage and experience disability two years out, according to a new study from Vivian Bykerk, M.D. at Hospital for Special Surgery. The research will be presented at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals on October 28 in San Diego.
A new study published in the latest edition of a leading medical journal has shown that treatment with ULTRACET® (37.5 mg tramadol hydrochloride/325 mg acetaminophen tablets) demonstrates similar efficacy and better tolerability than TYLENOL® with Codeine No. 3 when each is compared to placebo.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted an investigational new drug application (IND) to the Food and Drug Administration for a first-in-human study of RX-5902 to treat advanced or metastatic solid tumors.
› Verified 7 days ago
Pratima Saldanha, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 990 Stewart Ave, Garden City, NY 11530 Phone: 516-222-2022 Fax: 516-222-8475 | |
Dr. George Russell Autz, M.D. Radiology Medicare: May Accept Medicare Assignments Practice Location: 990 Stewart Ave., Garden City, NY 11530 Phone: 516-222-4294 Fax: 516-222-4880 | |
Stephanie Sims, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 990 Stewart Ave, Garden City, NY 11530 Phone: 516-222-2022 Fax: 516-222-8475 | |
Dr. Jeffrey Seth Reiner, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 990 Stewart Ave, Suite 400, Garden City, NY 11530 Phone: 516-222-2022 | |
Alice Y Kim, Radiology Medicare: Accepting Medicare Assignments Practice Location: 990 Stewart Ave, Garden City, NY 11530 Phone: 516-684-4774 | |
Daniel Settle, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 990 Stewart Ave, Garden City, NY 11530 Phone: 516-222-2022 Fax: 516-222-8475 | |
Michelle Beth Listhaus, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 990 Stewart Ave, Suite 100, Garden City, NY 11530 Phone: 516-222-4294 Fax: 516-222-4880 |